life sciences

Royalty Pharma, a PM Capital holding, is reshaping how breakthrough medicines are funded and developed. By Alex Warnaar, PM Capital

For this brand new episode of Finding the Front we are so fortunate to have biotech and life sciences veteran Matt Callahan on the show.

Michael & I discuss a variety topics, from his fund’s 80% performance this year to his thoughts on navigating the tech & biotech sectors.

Murdoch speaks with Michael Frazis the MD & PM of Frazis Capital Partners about AI, Tech, Life Sciences & his new A.I. risk management tool.

Murdoch speaks with Michael Frazis, the founder and portfolio manager at Frazis Capital Partners.

The life sciences industry played a central role in tackling the COVID-19 pandemic. Historically, it has taken a decade on average to develop a new vaccine. During...

Sector Overview The IIR Pharma & Biotech Index increased 2.9% in the month of June, in line with the broader market with the ASX All Ordinaries Accumulation Index up...

At midnight a couple of days ago the US Food and Drug Administration announced the approval of Biogen's Alzheimer's drug Aducanumab. Usually, when a drug is approved...

It's highly likely that over the past 12 months you have become acquainted with fresh-faced portfolio manager Michael Frazis. After all, he has graced the pages of...

This week Frazis Capital held its January strategy update. After the firm's long-only international equities fund advanced 108 per cent (after fees) up to December...